Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she plans to develop waiting time targets for receiving treatment in the eight new children and young people's gender services regional centres.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
There are no plans to develop tailored waiting time targets for receiving treatment in children and young people's gender services regional centres. NHS England has made significant progress on its overhaul of children’s gender identity services. NHS England closed the Tavistock Gender Clinic last month and opened two new, regional services operating under a fundamentally differing service model earlier this month. A third clinic is set to open in Bristol this Autumn, and NHS England has committed to a further three services by 2026. These new services will increase service capacity and reduce waiting lists.
Asked by: Theresa Villiers (Conservative - Chipping Barnet)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with NHS England on progress on improving outcomes for patients suffering from pancreatic cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Tackling cancer is a key priority for the Government. Ministers and officials continue to work closely with NHS England to increase positive outcomes for all cancer types, including pancreatic cancer. The National Health Service is delivering a range of interventions expected to increase early diagnosis and improve outcomes for those with pancreatic cancer. This includes: providing a route into pancreatic cancer surveillance for those at inherited high-risk, to identify lesions before they develop into cancer, and diagnose cancers sooner; creating new pathways to support faster referral routes for people with non-specific symptoms that could be linked to a range of cancer types; and increasing direct access for general practitioners to arrange diagnostic tests.
NHS England is also funding a new audit into pancreatic cancer to increase the consistency of access to treatments, and to stimulate improvements in cancer treatment and outcomes. The Royal College of Surgeons began work on this audit in October 2022, and the first report is expected in October 2024. In addition to this, the Getting it Right First Time team in NHS England is undertaking a deep dive into pancreatic cancer, which will highlight actions NHS providers need to take to improve services, as well as gathering examples of good practice to share.
The NHS is working towards its Long Term Plan ambition of diagnosing 75% of stageable cancers at stage one and two by 2028. Achieving this will mean that an additional 55,000 people each year will survive their cancer for at least five years after diagnosis. With progress made on reducing waiting times, cancer is being diagnosed at an earlier stage more often, with survival rates improving across almost all types of cancer.
Asked by: Gill Furniss (Labour - Sheffield, Brightside and Hillsborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase awareness of the symptoms of heart valve disease in women.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.
In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England’s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.
To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times. The centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.
In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the oral contribution by the Parliamentary Under Secretary of State at the Department of Health and Social Care during the debate on Covid-19: Response and Excess Deaths on Thursday 18 April 2024, Official Report, column 537, whether she has had recent discussions with (a) NICE and (b) the MHRA on their progress on reaching a decision on whether to recommend the use of Evusheld 2 to prevent covid-19.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department meets with the National Institute of Health and Care Excellence (NICE) regularly to discuss a range of issues, including access to medicines. The NICE has formally started its appraisal of AZD-3152, also known as sipavibart and referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible. If AZD-3152 is recommended as clinically and cost effective by the NICE, the National Health Service in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations.
Asked by: Caroline Lucas (Green Party - Brighton, Pavilion)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, with reference to the statement by the US Centres for Disease Control and Prevention entitled Highly Pathogenic Avian Influenza A (H5N1) Virus Infection Reported in a Person in the US, published on 1 April 2024, what assessment he has made of the level of risk posed by H5N1; and whether he has had discussions with the (a) Secretary of State for Health and Social Care and (b) Deputy Prime Minister and Chancellor of the Duchy of Lancaster on the potential implications for the UK Biological Security Strategy of that statement.
Answered by Mark Spencer - Minister of State (Department for Environment, Food and Rural Affairs)
We are in close contact with counterparts in the United States on the incidents of influenza of avian origin in cattle in the USA. We know that the strain of virus involved has not been detected in the UK.
We are working closely with the Department of Health and Social Care, UK Health Security Agency, Food Standards Agency and Cabinet Office officials and with international partners on risk assessments to consider the routes of incursion, animal to animal spread and animal to human spill-over and to review our well-tested surveillance mechanisms and preparedness activities in light of this emerging situation.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Medicines and Healthcare products Regulatory Agency on (a) its advice on prescribing and (b) the side effects of gabapentin.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Gabapentin is authorised for the treatment of some forms of epilepsy, as well as peripheral neuropathic pain. The product information for gabapentin, approved by the Medicines and Healthcare products Regulatory Agency (MHRA), provides information to support the prescribing of the medication including recommendations for dose, duration of use, as well as gradual reduction when stopping. The product information includes warnings about possible side effects.
The MHRA continuously monitors the safety of gabapentin and ensures the product information reflects what is known about the medicine and its side effects.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to educate current drug users on the risks of synthetic drugs.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is actively monitoring, and responding to, the continued threat posed by the growing levels of potent synthetic opioids in the United Kingdom. We are working to increase awareness of the dangers of synthetic opioids. The Government’s drug information and advice service, Talk to FRANK, aims to reduce drug misuse and its harms by increasing awareness among young people and parents. Information on synthetic opioids and the danger of their misuse is available at the following link:
https://www.talktofrank.com/drug/synthetic-opioids
Education on drug use is also a statutory component of relationships and sex education and health education in England. The Office for Health Improvement and Disparities and the Department for Education have commissioned lesson plans and other resources to support teachers in delivering quality drug prevention interventions. The lesson plans target primary and secondary students, teaching them how to manage influences and pressure, and keep themselves healthy and safe. These resources are being updated, and will have an increased emphasis on the risks of synthetic drugs.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to prevent increased synthetic drug use.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is actively monitoring, and responding to, the continued threat posed by the growing levels of potent synthetic opioids in the United Kingdom. We are working to increase awareness of the dangers of synthetic opioids. The Government’s drug information and advice service, Talk to FRANK, aims to reduce drug misuse and its harms by increasing awareness among young people and parents. Information on synthetic opioids and the danger of their misuse is available at the following link:
https://www.talktofrank.com/drug/synthetic-opioids
Education on drug use is also a statutory component of relationships and sex education and health education in England. The Office for Health Improvement and Disparities and the Department for Education have commissioned lesson plans and other resources to support teachers in delivering quality drug prevention interventions. The lesson plans target primary and secondary students, teaching them how to manage influences and pressure, and keep themselves healthy and safe. These resources are being updated, and will have an increased emphasis on the risks of synthetic drugs.
Asked by: Baroness Bennett of Manor Castle (Green Party - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the report Antibiotic underdosing and disposal in NHS organisations across Great Britain, published in November 2023; and what discussions they have had with the Care Quality Commission on integrating line flushing policies and practices into the assessment framework for care provided in England.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Officials are aware of, and have considered, the findings of the report Antibiotic underdosing and disposal in NHS organisations across Great Britain. Officials from the Department have not had any recent discussions with the Care Quality Commission on integrating line flushing policies and practices into the assessment framework for care provided in England.
General guidance on prescribing and the use of medicines is published by the National Institute for Health and Care Excellence in an online-only format. Good clinical practice is to flush an intravenous line with saline after a medicine has been administered, to ensure the full dose is delivered to the patient. This is not unique to antibiotics.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much the administration of the Vaccine Damage Payment Scheme cost the NHS Business Services Authority in (a) 2021, (b) 2022 and (c) 2023.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The NHS Business Services Authority (NHSBSA) administers the Vaccine Damage Payment Scheme, on behalf of the Department. Administration costs for the scheme were £600,000, £8.8 million, and £16.1 million for April 2021 to March 2022, April 2022 to March 2023, and April 2023 to March 2024, respectively. Payments made by the NHSBSA for the provision of medical records totalled £1,200, £72,000, and £73,100, for the same periods. The figures are provided to the nearest decimal place.